EphA2：乳腺癌治疗的有前途靶点。

EphA2: A promising therapeutic target in breast cancer.

机构信息

Department of the First Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, China.

Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China.

出版信息

J Genet Genomics. 2021 Apr 20;48(4):261-267. doi: 10.1016/j.jgg.2021.02.011. Epub 2021 Mar 29.

DOI:10.1016/j.jgg.2021.02.011

PMID:33962882

Abstract

Ephrin type-A receptor 2 (EphA2), a receptor tyrosine kinase, is overexpressed in human breast cancers often linked to poor patient prognosis. Accumulating evidence demonstrates that EphA2 plays important roles in several critical processes associated with malignant breast progression, such as proliferation, survival, migration, invasion, drug resistance, metastasis, and angiogenesis. As its inhibition through multiple approaches can inhibit the growth of breast cancer and restore drug sensitivity, EphA2 has become a promising therapeutic target for breast cancer treatment. Here, we summarize the expression, functions, mechanisms of action, and regulation of EphA2 in breast cancer. We also list the potential therapeutic strategies targeting EphA2. Furthermore, we discuss the future directions of studying EphA2 in breast cancer.

摘要

Ephrin 型-A 受体 2（EphA2）是一种受体酪氨酸激酶，在人乳腺癌中过表达，常与患者预后不良相关。越来越多的证据表明，EphA2 在与恶性乳腺癌进展相关的几个关键过程中发挥重要作用，如增殖、存活、迁移、侵袭、耐药性、转移和血管生成。由于通过多种方法抑制 EphA2 可以抑制乳腺癌的生长并恢复药物敏感性，因此 EphA2 已成为治疗乳腺癌的有前途的治疗靶点。在这里，我们总结了 EphA2 在乳腺癌中的表达、功能、作用机制和调节。我们还列出了针对 EphA2 的潜在治疗策略。此外，我们还讨论了研究 EphA2 在乳腺癌中的未来方向。